086450.KQ
DongKook Pharmaceutical Co., Ltd.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 21,800.00
−0.23%Year over year
Reported trailing growth
- Revenue
- +12.7%
- EBITDA
- +16.6%
- EBIT
- +16.9%
- EPS
- +25.3%
- Free cash flow
- -21.9%
- Operating cash flow
- +17.9%
Forward estimates
Based on analyst estimates
- Revenue
- -44.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +11.9%
- EBITDA
- +12.0%
- EBIT
- +9.3%
- Net income
- +7.7%
- EPS
- +7.3%
- Free cash flow
- +247.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026